Ipca Laboratories Reports Q1 FY27 Results: Standalone Net Profit Rises 42%, Consolidated Income Jumps 20%
Mumbai, August 13, 2026 – Ipca Laboratories Limited today announced its unaudited financial results for the first quarter (Q1) of the financial year 2026-27 ended June 30, 2026. The company reported significant growth across both standalone and consolidated performance metrics.The Group's standaloe Net Total Income rose 21% at Rs 2,136.66 crores for Q1 FY27. Furthermore, the standaloe Net Profit was recorded at Rs 373.29 crores, marking a 42% increase compared to the corresponding period in Q1 FY26.
Standalone Performance Highlights
The unaudited standalone results for Ipca Laboratories Limited show robust performance across its product lines and operational areas:| Particulars (Rs Crores) | Q1 FY27 | Q1 FY26 | Growth (%) |
|---|---|---|---|
| Revenue from Operations | 2,119.24 | 1,746.90 | 21% |
| Export Income | 935.39 | 699.76 | 34% |
| EBITDA before Forex (gain) / loss and other income | 556.82 | 416.04 | 34% |
| Net Profit after tax | 373.29 | 262.04 | 42% |
| Earnings per share (Re 1/-) | 14.71 | 10.33 | 42% |
Consolidated Financial Overview
The consolidated results reflected strong growth for the Group, with Total Income rising 20%. The comprehensive data for the quarter are summarized below:| Particulars (Rs Crores) | Q1 FY27 | Q1 FY26 | Growth (%) |
|---|---|---|---|
| Revenue from Operations | 2,788.10 | 2,308.85 | 21% |
| EBITDA before Forex (gain) / loss and other income | 637.94 | 424.58 | 50% |
| Net Profit after tax | 401.89 | 233.21 | 72% |
| Earnings per share (Re 1/-) | 15.84 | 9.19 | 72% |
Segmental and Operational Breakdown
The company operates primarily in the 'Pharmaceuticals' segment. Revenue from Operations for Q1 FY27 stood at Rs 2,119.24 crores, which is broken down across various categories:| Category | Sub-Segment | Q1 FY27 (Rs Crores) | Q1 FY26 (Rs Crores) |
|---|---|---|---|
| Formulations | Domestic | 1,082.12 | 961.01 |
| Formulations | Exports | 143.27 | 123.59 |
| Formulations | Institutional | 119.75 | 57.83 |
| Formulations | Generics | 340.02 | 268.19 |
| APIs | Domestic | 91.37 | 76.19 |
| APIs | Exports | 332.35 | 250.15 |
The Group's total revenue for Q1 FY27 reached Rs 2,788.10 crores. Of this, Indian formulations accounted for 1,685.16 crores (a 19% increase), while APIs totaled 423.72 crores (a 30% increase).
Other Business Developments
In addition to the financial results, the company provided details on various operational and strategic developments:- Labor Codes: The Company assessed the financial implications of the Labour Codes—which include provisions from the Code on Wages, 2019, and other related codes. This assessment resulted in an increase in gratuity and leave liability arising out of past service costs by Rs 45.82 crores for the year ended March 31, 2026, which was presented as an Exceptional Item.
- Amalgamation: The Board of Directors previously resolved to amalgamate M/s Krebs Biochemicals & Industries Ltd with Ipca Laboratories Limited, with an appointed date set for April 1, 2026. However, pending necessary consents and approvals, no effect from this amalgamation has been given in the unaudited financial results.
- Geographic Segmentation: The Group's operations are categorized in one segment, 'Pharmaceuticals.' Revenue breakdown across geographies showed India contributing Rs 1,229.21 crores, with Outside India generating Rs 1,558.89 crores during Q1 FY27.
IPCALAB Stock Price Movement
Today, shares of IPCA Laboratories Limited surged in the pharmaceutical sector, gaining 7.18% to close at ₹1893.4 after the trading session concluded. The stock saw a robustly traded volume of 779,280 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: